Korean Tickers
KRX in English

Home Markets Stocks Financials Guide

Newsfeed Insights Earnings Broker research

Korean Tickers
KRX in English

Home Markets Stocks Financials Guide

Newsfeed Insights Earnings Broker research

Market Pulse

Daily · Nov 5, 2026 · data.go.kr + ECOS

KOSPI

5,383.80

-300.00 (-5.28%)

KOSDAQ

678.41

-36.54 (-5.11%)

KOSPI 200

837.78

-51.47 (-5.79%)

USD/KRW

1,342.10

Home›Reports›214450

214450KOSDAQ·Jun 19, 2026

Lasting Value of Originals

PharmaResearchKB SecuritiesMinyoung Son

Read original PDF ↗

P

Source: KB Securities
Type: Company analysis
Language: English
Rating: Buy
Target price: KRW 430,000
Collected: Jul 03, 2026

The full report is published by KB Securities. Korean Tickers provides its source link and metadata.

More research on 214450

Diversification benefits set to buildMirae Asset Securities · Aug 18, 2026 Bottom confirmed; Rejuran remains resilientMirae Asset Securities · May 11, 2026 Three key factors to weighMirae Asset Securities · Feb 05, 2026 An inevitable valuation resetMirae Asset Securities · Nov 12, 2025 Rejuran to remain a staple in aesthetic medicineMirae Asset Securities · Oct 20, 2025 Stellar 2Q performance; 2H to be even betterMirae Asset Securities · Aug 12, 2025

All reports for 214450 →

Advertisement

Korean Tickers·Research reference for Korean listed companies.

Prices use KIS quote snapshots with data.go.kr daily fallback. Financials use DART; macro data uses ECOS.·Market data is informational and not investment advice.

KIS snapshots are refreshed every 30 minutes and are not a streaming quote feed.·Sources

Terms Refunds Disclaimer Privacy